163 related articles for article (PubMed ID: 2118862)
1. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid.
Loong EP; Wong FW
Fertil Steril; 1990 Sep; 54(3):530-1. PubMed ID: 2118862
[TBL] [Abstract][Full Text] [Related]
2. Transient shrinkage of a uterine leiomyosarcoma treated with GnRH agonist for a presumed uterine leiomyoma: comparison of magnetic resonance imaging finding before and during GnRH agonist treatment.
Kawamura N; Iwanaga N; Hada S; Maeda K; Sumi T; Ishiko O; Ogita S
Oncol Rep; 2001; 8(6):1255-7. PubMed ID: 11605044
[TBL] [Abstract][Full Text] [Related]
3. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
[TBL] [Abstract][Full Text] [Related]
4. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
5. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
[TBL] [Abstract][Full Text] [Related]
7. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
Matta WH; Shaw RW; Nye M
Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
[TBL] [Abstract][Full Text] [Related]
9. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
Maheux R; Lemay A; Turcot-Lemay L
Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of LHRH analogue action in uterine fibroids.
Shaw RW
Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
[TBL] [Abstract][Full Text] [Related]
11. Unsuspected uterine leiomyosarcoma discovered during treatment with a gonadotropin-releasing hormone analogue: a case report and literature review.
Milman D; Zalel Y; Biran H; Open M; Caspi B; Hagay Z; Dgani R
Eur J Obstet Gynecol Reprod Biol; 1998 Feb; 76(2):237-40. PubMed ID: 9481582
[TBL] [Abstract][Full Text] [Related]
12. Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma.
Kadhel P; Smail M; Borja De Mozota D
J Gynecol Obstet Hum Reprod; 2017 Sep; 46(7):609-611. PubMed ID: 28647614
[TBL] [Abstract][Full Text] [Related]
13. Uterine leiomyosarcomas coexistent with cellular and atypical leiomyomata in a young woman during the treatment with luteinizing hormone-releasing hormone agonist.
Lee WY; Tzeng CC; Chou CY
Gynecol Oncol; 1994 Jan; 52(1):74-9. PubMed ID: 8307505
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
Friedman AJ; Lobel SM; Rein MS; Barbieri RL
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
[TBL] [Abstract][Full Text] [Related]
16. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.
Matta WH; Stabile I; Shaw RW; Campbell S
Fertil Steril; 1988 Jun; 49(6):1083-5. PubMed ID: 2967195
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of uterine fibroma using LH-RH analogs and gestrinone. Limits and indications].
Erny R; Milliet E
Rev Fr Gynecol Obstet; 1990 Feb; 85(2):73-7. PubMed ID: 2108483
[TBL] [Abstract][Full Text] [Related]
18. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
Donnez J; Schrurs B; Gillerot S; Sandow J; Clerckx F
Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
[TBL] [Abstract][Full Text] [Related]
19. Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment.
Kawamura N; Ito F; Ichimura T; Shibata S; Umesaki N; Ogita S
Fertil Steril; 1997 Oct; 68(4):632-6. PubMed ID: 9341601
[TBL] [Abstract][Full Text] [Related]
20. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment.
Fernández-Montolí ME; Díez-Gibert O; Samaniego JM; Balagueró L; Navarro MA
Fertil Steril; 1995 Mar; 63(3):522-7. PubMed ID: 7851581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
